Paxlovid and Molnupiravir may change the course of the pandemic

Paxlovid and Molnupiravir may change the course of the pandemic. While the launch of vaccines has been a milestone in the fight against the virus, antiviral drugs remain at the center of the debate. And the World Health Organization is optimistic about them and what they will look like next year. Times of India.

Although vaccines seem to be the solution to return to normal, it is clear that drugs are also needed to treat COVID-19, and scientists have been working tirelessly since the advent of the new coronavirus to produce them. Drug companies have been looking for effective ways to reduce the spread of the virus and minimize the implications of COVID-19 infection.

You may also be interested in: On the first day of the year, Patriarch Daniel urges …


WHO believes new antiviral drugs will increase their chances of survival

According to Hans Kluge, the World Health Organization’s regional director for Europe, the new antiviral drugs against Covid-19 will significantly increase the chances of survival for critically ill patients.

The European Medicines Agency (EU Medicines Regulatory Authority) has recommended the administration of two antivirals – Paxlovid from Pfizer and Molnupiravir from Merck – before their official approval.

Paxlovid and Molnupiravir may change the course of the pandemic

“I am encouraged by the new antiviral drugs that are likely to be on the market in 2022, which will greatly increase the chances of survival of patients arriving in hospital with severe Covid-19,” Kluge told TASS.

You may also be interested in: New Year’s Eve ambulance interventions …

Both Paxlovid and Molnupiravir have been shown to reduce the chances of hospitalization or death from Covid-19 in high-risk patients by 89% and 30%, respectively.

Next-generation vaccines will be even more effective

According to Kluge, even more important is that next-generation vaccines will be more effective against new emerging strains.

“I cannot predict the future. But it should be noted that current vaccines are the first generation of Covid-19 vaccines. Future vaccines will be modified and adapted to new or emerging variants, making them more effective. This is no different from what is already happening with influenza vaccines, which are adapted to new strains of the flu almost every year, “said the WHO official.

You may also be interested in: France records daily infection records …

Paxlovid, also effective against Omicron

According to Pfizer, laboratory tests show that Paxlovid continues to be effective against the rapidly spreading Omicron variant.

For his part, Pfizer CEO Albert Bourla estimated that antivirals could prevent 1,200 deaths and 6,000 hospitalizations for every 100,000 infected patients receiving treatment.
The Medicines and Medicines Regulatory Agency (MHRA) last month approved the launch in the United Kingdom of Molnupiravir, the first oral antiviral approved for the treatment of mild to moderate forms of Covid in adults and which have at least one risk factor for evolution to a severe form of the disease. Lagevrio is the trade name for the drug in the UK. However, Molnupiravir is not recommended for pregnant women.

You may also be interested in: Carmen Harra, unexpected predictions. 2022, the year r …

Both Pfizer and Merck pills should be taken early, 3-5 days after infection with Covid, and require treatment with several pills for five days.

The information presented on this website is informative and does not replace the medical diagnosis or product leaflet. Any decision about your health should only be made after consultation with your doctor.


Source: DoctorulZilei by www.doctorulzilei.ro.

*The article has been translated based on the content of DoctorulZilei by www.doctorulzilei.ro. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!